Skip directly to content


  1. Global Atlas on Cardiovascular Disease Prevention and Control. Mendis S, Puska P, Norrving B, editors. World Health Organization, Geneva 2011. Accessed August 30, 2014.
  2. Laslett LJ, Alagona P Jr, Clark BA III, et al. The worldwide environment of cardiovascular disease: prevalence, diagnosis, therapy, and policy issues. A report from the American College of Cardiology. J Am Coll Cardiol. 2012;60(25 suppl S):S1-S49.
  3. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA CHF Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;128:e240-e327.
  4. McMurray JJV, Adamopoulos S, Anker SD, et al, for the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA). ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. 2012. Eur Heart J. 2012;33:1787-1847.
  5. Mahmood SS, Wang TJ. The epidemiology of congestive heart failure: contributions from the Framingham Heart Study. Global Heart. 2013;8(1):77-82.
  6. Centers for Disease Control and Prevention. Heart failure fact sheet. Accessed August 19, 2014.
  7. Cook C, Cole G, Asaria P, Jabbour R, Francis DP. The annual global economic burden of heart failure. Int J Cardiol. 2014;171(3):368-376.
  8. Go AS, Mozaffarian D, Roger VL, et al. Executive summary: heart disease and stroke statistics—2014 update: a report from the American Heart Association. Circulation. 2014;129:399-410.
  9. Murray-Thomas T, Cowie MR. Epidemiology and clinical aspects of congestive heart failure. J Renin Angiotensin Aldosterone Syst. 2003;4(3):131-136.
  10. Ambrosy AP, Fonarow GC, Butler J, et al. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol. 2014 Apr 1;63(12):1123-1133.
  11. Smith JJ, Levine HJ. Systolic dysfunction of the ventricle in congestive heart failure: pathophysiology, diagnosis, and therapy. Congest Heart Fail. 1999;5(1):10-26.
  12. Lloyd-Jones DM. The risk of congestive heart failure: sobering lessons from the Framingham Heart Study. Curr Cardiol Rep. 2001;3(3):184-190.
  13. Visser FC. Congestive heart failure: pathophysiology and management with special reference to systemic hypertension. J Cardiovasc Pharmacol. 1991;18(suppl 4):S8-S11.
  14. MacRae CA. The genetics of congestive heart failure. Heart Fail Clin. 2010;6(2):223-230.
  15. Komamura K. Similarities and differences between the pathogenesis and pathophysiology of diastolic and systolic heart failure. Cardiol Res Pract. 2013;824135.
  16. Savino JA III, Kosmas CE, Wagman G, Vittorio TJ. Evolution of the chronic congestive heart failure paradigm. Cardiol Rev. 2013;21(3):121-126.
  17. Khatibzadeh S, Farzadfar F, Oliver J, Ezzati M, Moran A. Worldwide risk factors for heart failure: a systematic review and pooled analysis. Int J Cardiol. 2013;168(2):1186-1194.
  18. Callendar T, Woodward M, Roth G, et al. Heart failure care in low- and middle-income countries: a systematic review and meta-analysis. PLoS Med. 2014;11(8):e1001699.
  19. Cowie MR, Wood DA, Coats AJS, et al. Incidence and aetiology of heart failure: a population-based study. Eur Heart J. 1999;20:421-428.
  20. Kannel WB. Incidence and epidemiology of heart failure. Heart Fail Rev. 2000;5(2):167-173.
  21. Zarrinkoub R, Wettermark B, Wändell P, et al. The epidemiology of heart failure, based on data for 2.1 million inhabitants in Sweden. Eur J Heart Fail. 2013;15(9):995-1002.
  22. Pitt B, Zannad F, Remme WJ, et al, for the Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341(10):709-717.
  23. Pitt B, Remme W, Zannad F, et al, for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14):1309-1321.
  24. Zannad F, McMurray JJV, Krum H, et al, for the EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11-21.
  25. Phelan D, Thavendiranathan P, Collier P, Marwick TH. Aldosterone antagonists improve ejection fraction and functional capacity independently of functional class: a meta-analysis of randomised controlled trials. Heart. 2012;98(23):1693-1700.
  26. Hu L-J, Chen Y-Q, Deng S-B, Du J-L, She Q. Additional use of an aldosterone antagonist in patients with mild to moderate chronic heart failure: a systematic review and meta-analysis. Br J Clin Pharmacol. 2013;75(5):1202-1212.
  27. Zhang L, Zhang S, Jiang H, et al. Effects of statin therapy on inflammatory markers in chronic heart failure: a meta- analysis of randomized controlled trials. Arch Med Res. 2010;41(6):464-471.
  28. Maggioni AP, Anker SD, Dahlström U, et al. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2013 Oct;15(10):1173-1184.
  29. Shah RV, Desai AS, Givertz MM. The effect of renin-angiotensin system inhibitors on mortality and hospitalization in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis. J Card Fail. 2010;16(3):260-267.
  30. Verdecchia P, Angeli F, Cavallini C, et al. Blood pressure reduction and renin-angiotensin system inhibition for prevention of congestive heart failure: a meta-analysis. Eur Heart J. 2009;30(6):679-688.